Pallas Capital Advisors LLC Buys New Shares in Envista Holdings Corporation $NVST

Pallas Capital Advisors LLC bought a new position in shares of Envista Holdings Corporation (NYSE:NVST) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 19,483 shares of the company’s stock, valued at approximately $513,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Envista in the 2nd quarter valued at about $25,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Envista by 16,711.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock valued at $31,000 after purchasing an additional 1,504 shares during the period. Allworth Financial LP raised its holdings in shares of Envista by 75.4% in the 4th quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock valued at $39,000 after purchasing an additional 776 shares during the period. UMB Bank n.a. lifted its stake in Envista by 46.1% in the 4th quarter. UMB Bank n.a. now owns 2,017 shares of the company’s stock valued at $44,000 after purchasing an additional 636 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Envista by 73.1% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock valued at $44,000 after purchasing an additional 949 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on NVST shares. Robert W. Baird set a $34.00 price target on Envista in a research report on Thursday, August 6th. Wall Street Zen cut Envista from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. JPMorgan Chase & Co. lifted their target price on Envista from $26.00 to $29.00 and gave the stock a “neutral” rating in a research note on Thursday, May 7th. Weiss Ratings raised Envista from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, August 6th. Finally, BMO Capital Markets assumed coverage on Envista in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $27.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Envista currently has an average rating of “Moderate Buy” and an average price target of $29.31.

Envista Stock Performance

Shares of NVST stock opened at $27.61 on Thursday. Envista Holdings Corporation has a 52 week low of $18.77 and a 52 week high of $30.42. The company has a market capitalization of $4.43 billion, a price-to-earnings ratio of 47.60, a PEG ratio of 1.33 and a beta of 0.86. The company has a 50-day simple moving average of $26.79 and a 200 day simple moving average of $26.25. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.43.

Envista (NYSE:NVST) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.07. Envista had a net margin of 3.33% and a return on equity of 7.88%. The firm had revenue of $730.50 million for the quarter, compared to analysts’ expectations of $716.11 million. During the same period in the prior year, the firm earned $0.26 EPS. The business’s revenue was up 7.1% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. On average, sell-side analysts predict that Envista Holdings Corporation will post 1.53 earnings per share for the current year.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.